Clinical Trials Browser

Withdrawn × Neuroendocrine Tumors × Clear all

NCT04432532 2025-02-10

NETAT

Adrenal Gland Neoplasms, Neuroendocrine Tumors

NCT00657332 2023-11-28

Clinical and Pathologic Studies in Neuroendocrine Tumors

Carcinoid Tumor, Neuroendocrine Tumors

NCT03623984 2023-09-11

Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers

Phase EARLY_PHASE1 Withdrawn

Carcinoid Tumor, Neuroendocrine Tumors

NCT04276597 2023-03-10

PUTNET

Phase 2 Withdrawn

CNSDermatologicEndocrineNET

Neoplasms, Unknown Primary, Paraganglioma, Pheochromocytoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04915144 2023-02-21

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Phase 2 Withdrawn

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Vipoma, Insulinoma, Gastrinoma, Neuroendocrine Tumors

NCT04713202 2023-02-10

NET-PACS

Phase 2 Withdrawn

Diarrhea, Neuroendocrine Tumors, Serotonin Syndrome

NCT04831567 2022-05-19

MIBNET

Phase 2 Withdrawn

Neuroendocrine Tumors

NCT04672876 2021-12-17

Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors

Phase 2 Withdrawn

Carcinoid Tumor, Neuroendocrine Tumors

NCT03923257 2021-06-08

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

Phase 1/2 Withdrawn

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04034745 2020-12-30

Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain

EndocrineGastrointestinalNET

Cachexia, Neoplasms, Pancreatic Neoplasms, Neuroendocrine Tumors

NCT03895463 2020-11-05

NETways

Neuroendocrine Tumors

NCT02030184 2019-10-17

Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas

Phase 1/2 Withdrawn

EndocrineNETThoracic

Lung Neoplasms, Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT02882503 2019-07-24

Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Small Benign Pancreatic Tumors

Phase NA Withdrawn

Neoplasms, Cystic, Mucinous, and Serous, Neuroendocrine Tumors

NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Phase 1 Withdrawn

DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

NCT01048086 2016-06-21

90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

Phase 2 Withdrawn

CNSEndocrineNET

Neuroblastoma, Neuroendocrine Tumors

NCT01860742 2016-04-05

CASTOR

Phase 3 Withdrawn

Neuroendocrine Tumors

NCT01864070 2014-07-22

Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease

Phase 1 Withdrawn

EndocrineGastrointestinalNET

Liver Neoplasms, Neuroendocrine Tumors